Minerva Neurosciences, Inc

NERVNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
4.96 USD
↗ 0.18 (3.77%)AT CLOSE (11:59 AM EDT)
4.83
↘ 0.13 (2.62%)
POST MARKET (AS OF 06:54 PM EDT)
Post Market
AS OF 06:54 PM EDT
4.83
↘ 0.13 (2.62%)
🔴Market: CLOSED
Open?$4.76
High?$4.98
Low?$4.45
Prev. Close?$4.78
Volume?114.1K
Avg. Volume?135.9K
VWAP?$4.74
Rel. Volume?0.84x
Bid / Ask
Bid?$4.27 × 100
Ask?$5.65 × 100
Spread?$1.38
Midpoint?$4.96
Valuation & Ratios
Market Cap?231.1M
Shares Out?46.6M
Float?33.2M
Float %?75.8%
P/E Ratio?N/A
P/B Ratio?-0.91
EPS?-$8.91
Dividend?0.00%
Ex-Dividend?N/A

NERV is currently priced at $4.96. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (163.4%) and a bullish Golden Cross on the moving averages.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Themes
Biotech - Drug Development›Neuroscience & CNS
Employees
7
Market Cap
231.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.minervaneurosciences.com
Listed
2014-07-01
Address
1500 DISTRICT AVENUE
BURLINGTON, MA 01803
Phone: 617-600-7373
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
61
Piotroski F-Score?0/9Weak
Altman Z-Score?-11.75Distress
Confidence?45%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?3.57%Low
Short Interest?1.2M
Days to Cover?10.7
Free Float33.2M
Avg Daily Volume110.6K
Settlement Date2026-05-15
Financial Health
Current Ratio?17.63Strong
Quick Ratio?17.63Strong
Cash Ratio?7.29Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-0.91CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
163.4%STRONG▾
ROA?
S&P
3
-441.4%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$198.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist